Ross Moat Biography and Net Worth

Executive Vice President, Chief Commercial Officer of Kiniksa Pharmaceuticals

Ross joined the Kiniksa team in 2019 and brings over 18 years’ experience in biopharmaceuticals, having led sales, marketing, commercial operations, market access and diagnostic functions within orphan and ultra-orphan disease fields. Prior to joining Kiniksa, Ross played a lead role towards the successful commercialization efforts for innovative gene therapies at Novartis Gene Therapies and Spark Therapeutics. Additionally, Ross served as the metabolic franchise commercial head at Alexion following the acquisition of Synageva. At Synageva, he was General Manager, UK & Ireland. Ross received his first-class BA (Honors) degree in Business Management from Middlesex University Business School in London.

What is Ross Moat's net worth?: The estimated net worth of Ross Moat is at least $258,253.45 as of May 5th, 2025. Mr. Moat owns 9,415 shares of Kiniksa Pharmaceuticals stock worth more than $258,253 as of May 31st. This net worth estimate does not reflect any other assets that Mr. Moat may own. Learn More about Ross Moat's net worth.
How do I contact Ross Moat?: The corporate mailing address for Mr. Moat and other Kiniksa Pharmaceuticals executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals can also be reached via phone at (781) 431-9100 and via email at ir@kiniksa.com. Learn More on Ross Moat's contact information.
Has Ross Moat been buying or selling shares of Kiniksa Pharmaceuticals?: During the last ninety days, Ross Moat has sold $2,811,430.14 of Kiniksa Pharmaceuticals stock. Most recently, Ross Moat sold 6,272 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $28.00, for a transaction totalling $175,616.00. Following the completion of the sale, the insider now directly owns 9,415 shares of the company's stock, valued at $263,620. Learn More on Ross Moat's trading history.
Who are Kiniksa Pharmaceuticals' active insiders?: Kiniksa Pharmaceuticals' insider roster includes Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals?: In the last year, insiders at the sold shares 29 times. They sold a total of 663,066 shares worth more than $16,703,670.09. The most recent insider tranaction occured on May, 28th when CEO Sanj K Patel sold 62,116 shares worth more than $1,697,630.28. Insiders at Kiniksa Pharmaceuticals own 54.6% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals.
Information on this page was last updated on 5/28/2025.

Ross Moat Insider Trading History at Kiniksa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/5/2025	Sell	6,272	$28.00	$175,616.00	9,415
5/1/2025	Sell	23,234	$28.02	$651,016.68	9,415
4/29/2025	Sell	64,035	$25.21	$1,614,322.35	9,415
4/21/2025	Sell	18,259	$20.29	$370,475.11	9,415

Ross Moat Buying and Selling Activity at Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $27.43

$26.58

$27.63

50 Day Range

MA: $23.62

$18.65

$27.78

2 Week Range

Now: $27.43

$17.38

$28.56

Volume

543,644 shs

Average Volume

492,782 shs

Market Capitalization

$2.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07